Get the Stockscreener App
1.41
1.06%
-0.01
Vivosim Labs Inc stock is traded at $1.41, with a volume of 7,015.
It is down -1.06% in the last 24 hours and down -17.84% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$1.42
Open:
$1.4
24h Volume:
7,015
Relative Volume:
0.05
Market Cap:
$4.07M
Revenue:
$142.00K
Net Income/Loss:
$-1.23M
P/E Ratio:
3.0277
EPS:
0.4657
Net Cash Flow:
$-10.62M
1W Performance:
-2.43%
1M Performance:
-17.84%
6M Performance:
-35.84%
1Y Performance:
-26.82%
1-Day Range:
$1.40
$1.48
1-Week Range:
$1.38
$1.5492
52-Week Range:
$1.25
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.405 | 4.11M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
What VivoSim Labs (VIVS) capital allocation tells us | Q3 2025: Better Than ExpectedGuidance Update - Newser
Can AI replace animal tests? VivoSim cites 96% diarrhea accuracy - Stock Titan
VIVS Price Today: VivoSim Labs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
VIVS VivoSim Labs notches 32.1 percent Q3 2025 revenue growth, shares edge higher on narrower than expected loss.AI Stock Signals - Newser
VivoSim Labs (VIVS) Stock: Is It a Compelling Buy (-4.35%) 2026-04-20Earnings Beat Stocks - Cổng thông tin điện tử Tỉnh Sơn La
VIVS Technical Analysis & ETF Price Forecast - Intellectia AI
Gap Down: Will VivoSim Labs Inc benefit from AI trendsEarnings Trend Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Esousa Group reports 9.9% stake in VivoSim Labs (NASDAQ: VIVS) - Stock Titan
VIVS SEC FilingsVivoSim Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VivoSim Labs Announces $4 Million Public Offering to Accelerate Adoption of 3D Human Tissue Models for Drug Testing - Minichart
VivoSim Labs Prices Best-Efforts Public Offering - TipRanks
VivoSim Labs Raises ~$2.5M in Initial Tranche; Signs Purchase and Placement Agreements - TradingView
VivoSim Labs (Nasdaq: VIVS) raises $3M in first tranche of $4M deal - Stock Titan
VivoSim Labs (NASDAQ: VIVS) registers 3.51M shares with detachable warrants - Stock Titan
VivoSim Announces Pricing of up to a $4 Million Public Offering - Sahm
VivoSim Labs prices $4 million public offering at $1.14/share By Investing.com - Investing.com Australia
VivoSim Labs prices $4M public offering at $1.14 per share - Investing.com Australia
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - au.finance.yahoo.com
VIVS Stock Analysis: VivoSim Labs Inc gains 13.68 percent to 1.62 amid bullish momentum - Cổng thông tin điện tử Tỉnh Sơn La
[EFFECT] VivoSim Labs, INC. SEC Filing - Stock Titan
VivoSim Labs (NASDAQ: VIVS) outlines $4M two-tranche stock and warrant financing - Stock Titan
Aug Breakouts: Is VivoSim Labs Inc benefiting from innovation trendsWeekly Gains Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-29 07:44:35 - baoquankhu1.vn
VivoSim Labs (NASDAQ: VIVS) files S-1 for $4M unit offering - Stock Titan
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing - GlobeNewswire
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Yahoo Finance
VivoSim Labs, Inc.: Fundamental Analysis and Financial Ratings | 4OR | US68620A3023 - marketscreener.com
Market Catalysts: What is the cash position of VivoSim Labs Inc2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Is VivoSim Labs Inc. stock a buy before product launchesJuly 2025 Rallies & Safe Capital Investment Plans - Naître et grandir
Buyback Watch: How much upside does VivoSim Labs Inc haveTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Why Is VIVS Stock Up 79% Today? - Stocktwits
VIVS Earnings History & Surprises | EPS & Revenue Results | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VivoSim names Raghunathan as VP of global sales By Investing.com - Investing.com Canada
VivoSim names Raghunathan as VP of global sales - Investing.com Nigeria
Vivosim appoints Arumugham (Ragoo) Raghunathan as vice president of global sales - marketscreener.com
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewswire
VIVS Should I Buy - Intellectia AI
VIVS Technical Analysis & Stock Price Forecast - Intellectia AI
Exit Recap: Is VivoSim Labs Inc showing insider buying2025 Trading Volume Trends & Weekly Chart Analysis and Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Travel Stocks: Does VivoSim Labs Inc have pricing powerJuly 2025 Patterns & Long-Term Capital Growth Ideas - baoquankhu1.vn
Rate Cut: Is VivoSim Labs Inc showing insider buyingQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Sectors Review: Is SmartKem Inc part of any ETFTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Is VivoSim Labs Inc. benefiting from innovation trends2025 EndofYear Setup & Precise Buy Zone Identification - mfd.ru
Why VivoSim Labs Inc. stock is rated strong buyJuly 2025 Review & Risk Controlled Daily Plans - mfd.ru
VIVS Financials: Income Statement, Balance Sheet & Cash Flow | VivoSim Labs Inc - Stock Titan
Aug Fed Impact: Is LXFRs ROE strong enough2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
VIVS Income Statement | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VivoSim (VIVS) to Present Innovative Data at SOT Meeting - GuruFocus
VivoSim to Debut Antibody Drug Conjugate Data, representing - GlobeNewswire
Shorts Report: Is VivoSim Labs Inc a stock for growth or value investors2025 Big Picture & Low Drawdown Trading Techniques - baoquankhu1.vn
Vivosim Labs Inc Stock (VIVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):